Entecavir

Spezifikationen

142217-69-4CAS-Nummer

604-279-5EG-Nummer

2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-oneIUPAC-Name

C12H15N5O3Chemische Formel

277.28 g/molMolekulargewicht

Entecavir; 142217-69-4; Baraclude; anhydrous entecavir; Entecavir anhydrous; BMS 200475; BMS-200475; entecavir (anhydrous); DTXSID4046446; NNU2O4609D; CHEBI:473990; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-; DTXCID2026446; SQ-34676; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-3H-purin-6-one; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-; Entecavirum; 2-amino-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl)-6,9-dihydro-3H-purin-6-one; RefChem:5792; J05AF10; BMS20047501; BMS-20047501; 604-279-5; 6H-Purin-6-One, 2-Amino-1,9-Dihydro-9-((1S,3R,4S)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl)-Monohydrate; 5968Y6H45M; 9-((1S,3R,4S)-4-Hydroxy-3-(Hydroxymethyl)-2-Methylenecyclopentyl)Guanine Monohydrate; BMS-200475-01; SQ34676; 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one; MFCD00907887; 2-AMINO-9-((1S,3R,4S)-4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL)-1H-PURIN-6(9H)-ONE; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1H-purin-6-one; Entecavir [USAN:INN]; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-1H-purin-6-one; 1333204-94-6; Entecavir (INN); Entecavir [INN]; 2-amino-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-1,9-dihydro-6H-purin-6-one; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one; UNII-NNU2O4609D; Entecavir sodium; HSDB 7334; NCGC00164563-01; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylene-cyclopentyl]-1H-purin-6-one; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-, [1S-(1a,3a,4ss)]-; BMS 200475; Baraclude; Entecavir; SQ 34676; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one; ENTECAVIR [MI]; ENTECAVIR [HSDB]; CHEMBL713; ENTECAVIR [WHO-DD]; SCHEMBL28648; Baraclude, BMS 200475; SCHEMBL367156; (1R,3S,4S)-ent-Entecavir; orb1226313; orb1310954; Entecavir, >=98% (HPLC); SCHEMBL15198001; 2-amino-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-1,9-dihydro-6H-purin-6-one; QDGZDCVAUDNJFG-FXQIFTODSA-N; GLXC-07996; MSK10442; Tox21_112192; BDBM50248008; EBC-26411; MFCD11046562; AKOS015854916; AKOS015920226; AKOS025312554; AC-1593; CCG-267218; CS-3160; DB00442; GS-6386; 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylene-cyclopentyl]-3H-purin-6-one; NCGC00164563-04; NCGC00164563-06; NCGC00164563-09; NCGC00164563-11; NCGC00164563-13; HY-13623; SY028610; SQ 34,676; CAS-142217-69-4; E0899; E5576; D07896; AR-270/43507901; EN300-37158607; F093332; Q418586; BRD-K08206212-001-01-2; BRD-K08206212-002-01-0; 9-[(1S,3R,4S)-4-Hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]guanine; 2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-3,9-dihydro-purin-6-one; 2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylenecyclopentyl]-1,9-dihydro-6H-purin-6-one; 6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]; EntercavirSynonyme